IP Library › Patent Application 19172267
Patent Application
App. No. 19/172,267

BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/172,267
Abstract

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (25)

1 . An engineered polypeptide having proline hydroxylase activity comprises an amino acid sequence having at least 85% sequence identity to reference sequence SEQ ID NO: 4 and one or more residue differences as compared to SEQ ID NO: 4 at positions selected from 30, 37, 62, 82, 97, 114, 151, 158, 160, 161, 189, 207, 263, 271, and 273, wherein the residue difference at positions 30, 62, 114, 151, and 171, are S30N/R, A62D, E114S, M151R, and H271W.

2 . The engineered polypeptide of claim 1 , wherein the residue difference at positions 37, 82, 97, 158, 160, 161, 189, 207, 263, and 273 are C37I, T82K, V97A, C158N, S160R, K161P, F176V, T189I, G207R, S263D, and E273T.

3 . The engineered polypeptide of claim 1 , wherein the residue differences as compared to SEQ ID NO: 4 are selected from S30N, S30R, C37I, A62D, T82K, V97A, E114S, M151R, C158N, S160R, K161P, T189I, G207R, S263D, H271W, and E273T.

4 . The engineered polypeptide of claim 1 , wherein said polypeptide further comprises one or more residue differences as compared to SEQ ID NO: 4 at residue positions selected from: 13, 14, 24, 26, 27, 57, 61, 72, 76, 77, 81, 86, 88, 127, 128, 142, 163, 173, 175, 178, 180, 184, 185, 186, 187, 188, 191, 192, 195, 198, 200, 209, 210, 211, 213, 215, 217, 218, 222, 225, 230, 233, 236, 238, 240, 241, 256, 259, and 265.

5 . The engineered polypeptide of claim 1 , wherein said polypeptide comprises a residue difference or residue difference set selected from:

(a) F176V;

(b) M151R/F176V;

(c) S30R/C37I/L76V/M151R/S160R/F176V;

(d) S30R/C37I/V97A/M151R/S160R/F176V;

(e) S30R/C37I/L76V/V97A/M151R/S160R/F176V;

(f) S30R/C37I/V57A/V97A/M151R/S160R/F176V;

(g) S30N/C37I/V57A/A62D/V97A/E114S/M151R/S160R/F176V/H271W/E272T;

(h) R26A/S30N/C37I/V57A/A62D/T82K/V97A/E114S/M151R/C158N/S160R/K161P/F176V/H271W/E272 T; and

(i) R26A/S30N/C37I/V57A/A62D/T82K/V97A/E114S/M151R/C158N/S160R/K161P/F176V/T189I/G207R/S263D/H271W/E272T.

6 . The engineered polypeptide of claim 1 , wherein said polypeptide has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the even-numbered sequences in SEQ ID NOS:6-1004.

7 . The engineered polypeptide of claim 1 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid.

8 . The engineered polypeptide of claim 7 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid with at least 1.2 fold, 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold or more the activity of the naturally occurring enzyme.

9 . The engineered polypeptide of claim 7 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid with greater than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more diastereomeric excess of (2S,5R)-5-hydroxypipecolic acid.

10 . A polynucleotide encoding the engineered polypeptide of claim 1 .

11 . The polynucleotide of claim 10 , wherein said polynucleotide comprises a nucleic acid sequence optimized for expression in E. coli.

12 . An expression vector comprising the polynucleotide of claim 10 , optionally further comprising at least one control sequence.

13 . The expression vector of claim 12 , wherein said vector comprises SEQ ID NO:1007, 1008, or 1009.

14 . A host cell comprising the polynucleotide of claim 10 .

15 . A method of preparing an engineered polypeptide, comprising culturing the host cell of claim 18 , under conditions suitable for expression of the polypeptide.

16 . The method of claim 15 , further comprising a step of isolating the engineered polypeptide.